Skip to main content

Advertisement

Table 2 Distribution of failure, suboptimal and optimal collections in the whole population

From: Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study

Parameters Failure Sub-Optimal Optimal
Number (%) Number (%) Number (%)
Whole population    
Outcome 167 (12.39) 113 (8.38) 1068 (79.23)
Age    
 <60 years 80 (10.15) 57 (7.23) 651 (82.61)
 ≥60 years 87 (15.54) 56 (10.00) 417 (74.46)
Lenalidomide use    
 No 113 (11.39) 78 (7.86) 801 (80.75)
 Yes 54 (15.17) 35 (9.83) 267 (75.00)
Hematological toxicity    
 No 132 (10.48) 106 (8.41) 1022 (81.11)
 Yes 35 (39.77) 7 (7.95) 46 (52.27)
Baseline cytopenia    
 No 117 (11.52) 80 (7.87) 819 (80.61)
 Yes 50 (15.06) 33 (9.94) 249 (75.00)
  1. Absolute numbers and percentages of failures, suboptimal and optimal collections, according to the presence of different risk factors in 1,348 newly diagnosed myeloma patients. Failure: CD34+ PBSC <2 × 106/kg; Suboptimal: CD34+ PBSC >2 and <5 × 106/kg; Optimal: CD34+ PBSC >5 × 106/kg. PBSC, peripheral blood stem cells.